Senate Vioxx Hearing Looks Like Tough Going For Merck, Pfizer

The first Congressional hearing into the withdrawal of Vioxx is likely to put both Merck and FDA on the defensive for their handling of safety data - and could revive similar allegations about Pfizer involving calcium channel blockers